Anavex Life Sciences Corp. (NASDAQ:AVXL)’s traded shares stood at 1.91 million during the last session, with the company’s beta value hitting 0.79. At the close of trading, the stock’s price was $9.51, to imply a decrease of -0.31% or -$0.03 in intraday trading. The AVXL share’s 52-week high remains $15.24, putting it -60.25% down since that peak but still an impressive 25.03% since price per share fell to its 52-week low of $7.13. The company has a valuation of $799.98M, with an average of 1.24 million shares in intraday trading volume over the past 10 days and average of 1.18 million shares over the past 3 months.

Analysts have given a consensus recommendation of a Buy for Anavex Life Sciences Corp. (AVXL), translating to a mean rating of 1.80. Of 4 analyst(s) looking at the stock, 0 analyst(s) give AVXL a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.19.

Anavex Life Sciences Corp. (NASDAQ:AVXL) trade information

After registering a -0.31% downside in the last session, Anavex Life Sciences Corp. (AVXL) has traded red over the past five days. The stock hit a weekly high of 9.86 this Friday, 03/17/23, dropping -0.31% in its intraday price action. The 5-day price performance for the stock is 5.90%, and -9.17% over 30 days. With these gigs, the year-to-date price performance is 2.70%. Short interest in Anavex Life Sciences Corp. (NASDAQ:AVXL) saw shorts transact 18.37 million shares and set a 12.43 days time to cover.

Analysts on Wall Street suggest a consensus price target of $43.75, implying an increase of 78.26% to the stock’s current value. The extremes give us $28.00 and $58.00 for target low and target high price respectively. As such, AVXL has been trading -509.88% off suggested target high and -194.43% from its likely low.

Anavex Life Sciences Corp. (AVXL) estimates and forecasts

Looking at statistics comparing Anavex Life Sciences Corp. share performance against respective industry, we note that the company has underperformed competitors. Revenue is forecast to shrink -35.70% this quarter before falling -25.00% for the next one.

AVXL Dividends

Anavex Life Sciences Corp. has its next earnings report out between May 08 and May 12. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Anavex Life Sciences Corp. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.

Anavex Life Sciences Corp. (NASDAQ:AVXL)’s Major holders

Anavex Life Sciences Corp. insiders hold 3.04% of total outstanding shares, with institutional holders owning 32.16% of the shares at 33.17% float percentage. In total, 32.16% institutions holds shares in the company, led by Blackrock Inc. As of Sep 29, 2022, the company held over 5.31 million shares (or 6.81% of shares), all amounting to roughly $54.84 million.

The next major institution holding the largest number of shares is State Street Corporation with 4.36 million shares, or about 5.59% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $45.01 million.

We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund as the top two Mutual Funds with the largest holdings of the Anavex Life Sciences Corp. (AVXL) shares. Going by data provided on Dec 30, 2022, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 4.45 million shares. This is just over 5.70% of the total shares, with a market valuation of $41.2 million. Data from the same date shows that the other fund manager holds a little less at 2.27 million, or 2.91% of the shares, all valued at about 23.39 million.